Achaogen Company Profile (NASDAQ:AKAO)

Analyst Ratings

Consensus Ratings for Achaogen (NASDAQ:AKAO) (?)
Ratings Breakdown: 2 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $12.67 (222.31% upside)

Analysts' Ratings History for Achaogen (NASDAQ:AKAO)
Show:
DateFirmActionRatingPrice TargetActions
6/14/2016WedbushUpgradeNeutral -> Outperform$7.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/10/2015Cantor FitzgeraldReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2015Credit Suisse Group AGDowngradeOutperform -> Underperform$22.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/3/2014SunTrust Banks Inc.Initiated CoverageBuy$22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2014Canaccord GenuityInitiated CoverageBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/19/2014GabelliUpgradeHold -> Buy$19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Achaogen (NASDAQ:AKAO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
3/15/2016Q414($0.58)($0.61)$5.33 million$4.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015($0.45)($0.48)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015($0.20)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015($0.26)($0.34)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015($0.33)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.25)($0.47)$6.00 million$4.52 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.19)($0.20)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.48)($1.00)$5.39 million$6.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Achaogen (NASDAQ:AKAO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.71)($0.52)($0.62)
Q2 20164($0.71)($0.52)($0.62)
Q3 20164($0.56)($0.39)($0.49)
Q4 20164($0.58)($0.29)($0.48)
Q1 20171($0.49)($0.49)($0.49)
Q2 20171($0.54)($0.54)($0.54)
Q3 20171($0.59)($0.59)($0.59)
Q4 20171($0.55)($0.55)($0.55)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Achaogen (NASDAQ:AKAO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Achaogen (NASDAQ:AKAO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/17/2016Ian FriedlandInsiderSell1,772$3.22$5,705.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Kenneth J HillanCEOSell3,572$3.22$11,501.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Achaogen (NASDAQ:AKAO)
DateHeadline
07/23/16 02:24 PMStock Up Nicely This Week: Achaogen, Inc. (NASDAQ:AKAO) - TGP
07/22/16 10:36 AMEarnings Focus and Crowd Sourced Sentiment Review for Achaogen, Inc. (NASDAQ:AKAO) - TGP
07/21/16 07:58 PMBroker Outlook For Achaogen, Inc. (AKAO) - Fiscal Standard
07/21/16 02:24 PMAchaogen Inc Increases Again; Strong Momentum for Buyers - Press Telegraph
07/21/16 02:24 PMAchaogen Inc's Trend Up, Especially After Today's Strong Session - Consumer Eagle
07/20/16 09:51 PMIs Achaogen Inc's Fuel Running Low? The Stock Just Declined Again - Consumer Eagle
07/20/16 09:51 PMIncreased Stock Volatility Watch: Achaogen, Inc. (NASDAQ:AKAO) - Engelwood Daily
07/20/16 09:51 PMShares Jumping Higher in Session: Achaogen, Inc. (NASDAQ:AKAO) - TGP
07/20/16 09:51 PMAchaogen Inc. (AKAO) Jumps 9.63% on July 20 - Equities.com
07/20/16 03:29 PMAchaogen Inc : LifeSci Capital Initiates Coverage of Achaogen
07/19/16 07:51 PMAchaogen Incorporated (NASDAQ:AKAO) Sellers Increased By 30.9% Their Shorts - Consumer Eagle
07/19/16 12:45 PMLifeSci Capital Initiates Coverage of Achaogen - [Accesswire] - Developing Potent Antibiotics to Treat Serious Multi-Drug Resistant Infections Report Available here: www.lifescicapital.com/equity-research/achaogen/ NEW YORK, NY / ACCESSWIRE / July 19, 2016 / LifeSci ...
07/18/16 02:27 PMInvestor Watch: Volatility Recap on Shares of: Achaogen, Inc. (NASDAQ:AKAO) - Engelwood Daily
07/18/16 07:45 AMCerulean Pharma (CERU) Worth a Look: Stock Gains 9.1% -
07/17/16 07:10 AMStrong Sell Calls For Achaogen, Inc. (NASDAQ:AKAO) At 0 - Investor Newswire
07/16/16 02:24 PMAchaogen Incorporated (NASDAQ:AKAO) Sellers Increased By 44.43% Their Shorts - Press Telegraph
07/15/16 06:41 PMNew Broker Ratings For Achaogen, Inc. (AKAO) - FTSE News
07/15/16 06:41 PMShares Experiencing a Downtrend: Achaogen, Inc. (NASDAQ:AKAO) - TGP
07/15/16 01:00 PMIncreased Volatility Noted on Shares of: Achaogen, Inc. (NASDAQ:AKAO) - Engelwood Daily
07/15/16 07:28 AMAchaogen to Host Key Opinion Leader Meeting on Multi-Drug Resistant Infections on July 19, 2016 in New York - [at noodls] - SOUTH SAN FRANCISCO, Calif., July 15, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) ...
07/15/16 07:25 AMFoamix Pharmaceuticals (FOMX) Jumps: Stock Rises 7.1% -
07/12/16 02:28 PMInstitutional Investor Sentiment About Achaogen Inc (NASDAQ:AKAO) Increased - Press Telegraph
07/12/16 07:32 AMTrading Performance and Target Watch for Achaogen, Inc. (NASDAQ:AKAO) - Press Telegraph
07/11/16 07:29 PMWill Achaogen Inc Short Squeeze Soon? The Stock Formed a Bearish Double Bottom Pattern - Consumer Eagle
07/11/16 02:25 PMAchaogen, Inc. (NASDAQ:AKAO) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/10/16 02:23 PMNext Weeks Broker Price Targets For Achaogen, Inc. (AKAO) - Fiscal Standard
07/10/16 07:09 AMIs $12 Within Reach For Achaogen, Inc. (NASDAQ:AKAO)? - Investor Newswire
07/08/16 10:28 AMWall Street Ratings and Target Price Views on Achaogen, Inc. (NASDAQ:AKAO) - Telanagana Press
07/07/16 02:26 PMAchaogen, Inc. (NASDAQ:AKAO) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/06/16 07:13 AMStock Rating Watch and Earnings Insight for Achaogen, Inc. (NASDAQ:AKAO) - Press Telegraph
07/06/16 07:13 AMAchaogen, Inc. (AKAO) Current Analyst Ratings - Fiscal Standard
07/06/16 07:13 AMAchaogen Inc. (AKAO) Jumps 5.01% on July 04 - Equities.com
07/05/16 07:12 AMAchaogen Inc Stock Is Rising Now - Press Telegraph
07/03/16 07:10 AMAchaogen, Inc. (NASDAQ:AKAO) Expected to Reach Highs Of $12 - Investor Newswire
07/01/16 07:39 PMAchaogen Inc. (AKAO) Jumps 5.01% on July 01 - Equities.com
07/01/16 02:26 PMShares Headed Up in Session: Achaogen, Inc. (NASDAQ:AKAO) - Telanagana Press
06/30/16 02:27 PMAchaogen, Inc. (NASDAQ:AKAO) Company Rating and Target Watch - Telanagana Press
06/29/16 07:34 PMAchaogen Incorporated (NASDAQ:AKAO) Short Interest Increased By 44.43% - Engelwood Daily
06/29/16 07:34 PMWatching Stock Volatility for: Achaogen, Inc. (NASDAQ:AKAO) - Engelwood Daily
06/29/16 02:23 PMShare Update and Earnings Review for Achaogen, Inc. (NASDAQ:AKAO) - Press Telegraph
06/26/16 02:22 PMAchaogen, Inc. (AKAO) Broker Price Targets For The Coming Week - Fiscal Standard
06/26/16 07:22 AMStrong Sell Calls Recommendations For Achaogen, Inc. (NASDAQ:AKAO) At 0 - Investor Newswire
06/24/16 03:09 PMACHAOGEN INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Shee -
06/24/16 09:46 AMAchaogen Inc. (AKAO) Drops 5.19% on June 22 - Equities.com
06/24/16 07:10 AMAchaogen Announces New Employment Inducement Grants - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 24, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) ...
06/22/16 07:12 AMAchaogen Inc. (AKAO) Drops 5.53% on June 20 - Equities.com
06/21/16 02:23 PMAchaogen : Plazomicin Highlighted in Multiple Presentations at ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens
06/20/16 01:00 PMETF’s with exposure to Achaogen, Inc. : June 20, 2016 -
06/20/16 08:09 AMAchaogen's Plazomicin Highlighted in Multiple Presentations at ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens - [at noodls] - SOUTH SAN FRANCISCO, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant (MDR) ...
06/20/16 07:30 AMAchaogen’s Plazomicin Highlighted in Multiple Presentations at ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens - [GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., June 20, 2016-- Achaogen, Inc., a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant gram-negative infections, today announced ...

Social

About Achaogen

Achaogen logoAchaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AKAO
  • CUSIP:
Key Metrics:
  • Previous Close: $3.82
  • 50 Day Moving Average: $3.99
  • 200 Day Moving Average: $3.68
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $72.34M
  • Beta: 0.53
  • Current Year EPS Consensus Estimate: $-2.34 EPS
  • Next Year EPS Consensus Estimate: $-2.01 EPS
Additional Links:
Achaogen (NASDAQ:AKAO) Chart for Saturday, July, 23, 2016